Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Shared Genomic Segment Analysis and Tumor Subtyping in High-Risk BrCa Pedigrees

PROVIDER: PRJNA721012 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14202900_1.fastq.gz	Fastqsanger.gz
	SRR14202900_2.fastq.gz	Fastqsanger.gz
	SRR14203000_1.fastq.gz	Fastqsanger.gz
	SRR14203000_2.fastq.gz	Fastqsanger.gz
	SRR14203100_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 763

Similar Datasets

Shared Genomic Segment Analysis and Tumor Subtyping in High-Risk BrCa Pedigrees

Project description:Shared Genomic Segment Analysis and Tumor Subtyping in High-Risk BrCa Pedigrees

| PRJNA494903 | ENA

Shared Genomic Segment Analysis and Tumor Subtyping in High-Risk BrCa Pedigrees

Project description:Shared Genomic Segment Analysis and Tumor Subtyping in High-Risk BrCa Pedigrees

| PRJNA494904 | ENA

Molecular subtyping of breast cancer by transcription profiling

Project description:Breast cancer was one of the first cancer types where molecular subtyping led to explanation of interpersonal heterogeneity and resulted in improvement of treatment regimen. Several multigene classifiers have been developed and in particular those defining molecular signatures of early breast cancers possess significant prognostic information. Hence since 2014, molecular subtyping of primary breast cancers was implemented as a part of routine diagnostics with direct impact of therapy assignment. In this study, we evaluate direct and potential benefits of molecular subtyping in low-risk breast cancers as well as present the advantages of a robust molecular signature in regard to patient work-up among high-risk breast cancers.

2017-12-01 | E-MTAB-5724 | biostudies-arrayexpress

Transcriptomic characterization of heterogeneity in paired primary and recurrent HNSCC tumors

Project description:Despite aggressive multi-modal treatment, advanced head and neck squamous cell carcinoma (HNSCC) patients are at high risk of recurrence. n=19 different selected areas of matched pairs (n=3) of primary/recurrent tumor specimens were subjected to RNA sequencing. Transcriptional subtyping (classical/CL, basal/BA, inflamed-mesenchymal/IMS) in matched primary and recurrent HNSCC specimens revealed heterogeneity.

2022-04-08 | GSE186461 | GEO

miRNA profiling in Breast Cancer

Project description:To exploit molecular subtyping for risk stratification in breast cancer patients

2024-01-01 | E-MTAB-13550 | biostudies-arrayexpress

Genomic analysis of low-grade serous ovarian carcinomas [ILOE]

Project description:Low-grade serous ovarian carcinomas are typically Ras-pathway mutated, TP53 wild-type, have limited chromosomal aberration, and are frequently associated with borderline tumors. By contrast, high-grade serous ovarian carcinoma lack Ras-pathway mutations, are invariably TP53 mutated, show widespread genomic change, and are commonly BRCA-pathway disrupted. We sought to identify differences in genomic copy number changes in borderline and invasive components of serous carcinoma. Borderline and invasive tumor components were profiled from patients with LGSC

2014-10-01 | E-GEOD-57270 | biostudies-arrayexpress

Progression of Neuroblastoma Tumor

Project description:Previous studies have reported that metastatic tumor cells acquire genomic aberrations compared to those present in the primary due to an unstable genome. However, it is not clear if all malignancies follow a similar pattern. Neuroblastoma is the most common extra-cranial solid tumor of childhood. To examine how the neuroblastoma genome changes during tumor progression, we investigated chromosomal structural alterations across three tumors from a patient with hisg-risk neuroblastoma. The tumors included the primary tumor, one metastatis collected at diagnosis before any treatment, and a second metastatis collected during post mortem investigation. The recapitulated chromosomal structural alterations demonstrated that all three tumors had extensive chromosomal alterations involving virtually every chromosome. All tumors were aneuploid and shared many chromosomal alterations often seen in neuroblastoma. Despite some tumor to tumor structural variability, approximately 81-91% of the altered regions were shared among the three tumor genomes with primary tumor and pre-treamment metastatis being the most similar. Three samples from one patient with high-risk neuroblastoma. Primary tumor plus two metastatic tumors. One of metastasis sampled at diagnosis, before any treatment, and second metastasis taken at autopsy.

2011-12-01 | E-GEOD-33987 | biostudies-arrayexpress

Agilent 244A aCGH array for comparison of lung tumor CNA to high-throughput sequencing data

Project description:1 lung tumor was profiled for copy-number alterations with the high-resolution Agilent 244A aCGH Array. One lung tumor sample were assayed on the Agilent Human Genome CGH 244A Microarrays with the intent of comparing the genomic alterations reported by the array platform with those reported by high-thoughput sequencing. Human male genomic DNA (Promega P/N G1471) was used as reference. Individual log2 ratios of background subtracted signal intensities were obtained from the Agilent Feature Extraction software version 9.5. The log2 ratios were centered to a median of zero and the resulting log2 ratio values for each probe were segmented using GLAD. All probes within the genomic bounds of a given GLAD-derived segment were given the mean copy number value of probes within that segment.

2010-05-27 | E-GEOD-20574 | biostudies-arrayexpress

Agilent 244A aCGH array for breast, lung, melanoma, ovary, and prostate

Project description:373 tumors were profiled for copy-number alterations with the high-resolution Agilent 244A aCGH Array. Tumor samples were assayed on Agilent Human Genome CGH 244A Microarrays with the intent of surveying the landscape of genomic alterations in 5 tumor types. Human male genomic DNA (Promega P/N G1471) was used as reference. Individual log2 ratios of background subtracted signal intensities were obtained from the Agilent Feature Extraction software version 9.5. The log2 ratios were centered to a median of zero and the resulting log2 ratio values for each probe were segmented using GLAD. All probes within the genomic bounds of a given GLAD-derived segment were given the mean copy number value of probes within that segment.

2010-07-29 | E-GEOD-20393 | biostudies-arrayexpress

Gene expression analysis of CALGB 9741 patient tumor samples using the nCounter RUO-PAM50 signature

Project description:Intrinsic subtyping of breast cancer was performed using an nCounter RUO-PAM50 gene expression assay to determine the ability of instrinsic subtyping to predict what patients may benefit from altered chemotherapy scheduling in the CALGB 9741 clinical trial population. FFPE primary breast tumor samples archived at the CALGB Pathology Coordinating Office (PCO) were used to obtain total RNA for instrinsic subtyping using the nCounter Analysis System. Gene-expression profiles were generated for 1321 of 1471 patient samples (90%) suitable for inclusion in this study.

2015-11-10 | E-GEOD-74821 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data